Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

The first incarnation of Westinghouse Electric Corporation, an American manufacturing company, was founded on January 8, 1886 by George Westinghouse. It was originally named Westinghouse Electric Company, and was renamed Westinghouse Electric Corporation in 1945. The company acquired the CBS television network in 1995, and was renamed CBS Corporation before being acquired by Viacom in 1999.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Delix Therapeutics, Inc. is an American company located in Palo Alto, CA, that develops therapeutics to reduce and alleviate mental suffering. The firm was founded by David E. Olson, Nicholas Haft and Nick Haft. Mark Rus is the current CEO, occupying that position since 2021.\nThe company says this about itself: Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company's compounds are easily manufactured small molecules capable of rapidly inducing structural and functional neural changes in targeted areas of the brain. Many of these molecules are inspired by psychedelic compounds and preserve their efficacy-promoting mechanisms while avoiding their hallucinogenic properties and other safety liabilities. Delix is rapidly advancing these compounds through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. Headquartered in Massachusetts, Delix is building a world-class biotechnology company by combining an experienced team with innovative treatment strategies and scientific rigor to address the significant and growing mental health challenges impacting society.

Shanghai Dendritic Precision Instrument Co., Ltd., established on 2018-01-24, Business scope includes precision instruments,electronic product,communication device,Electronic Component,Sales of computer hardware and software,computer system integration,engaged in electronics,Technology development in the field of computer science and technology,technology transfer,technical consulting,Technical Services,industrial product design,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

ZEON Corp. engages in the production and sale of synthetic rubbers and specialty plastics. It operates through the following segments: Elastomer Materials Business, Specialty Materials Business, and Others. The Elastomer Materials Business segment includes synthetic rubbers used in automobile tires and conveyer belts; synthetic lattices used in tires and adhesives; and chemical products such as resins and inks. The Specialty Materials Business segment comprises of synthetic aroma chemicals and other industrial chemicals; information and imaging materials; specialty plastics for optical lenses; and medical products. The Others segment consists of paints, butadiene extraction technology, and reaction injection molding (RIM) formulations and products. The company was founded on April 12, 1950 and is headquartered in Tokyo, Japan.

Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA.

Shenzhen Winafi Biotechnology Co., Ltd., established on 2014-11-06, Business scope includes general business items:Biotechnology R&D,Technical Services;Domestic Trade(Does not contain franchise,Exclusive control,Monopoly).,The licensing program is:

Chengdu Enxi Medical Management Group Co., Ltd., established on 2019-07-05, Business scope includes licensed projects:Class III medical device business;Drug Wholesale(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:hospital management;Business Management Consulting;Corporate Headquarters Management;brand management;Commercial Complex Management Services;business management;Single-purpose commercial prepaid card agency sales;Sales of Class I Medical Devices;Sales of Class II Medical Devices;software sales;Clothing and apparel wholesale;Big data service;software development;Medical Research and Experimental Development;advertisement making;Advertising Design,acting;HR Services(Excludes job brokerage activities,Labor dispatch service);Biochemical product technology research and development;Cosmetics Wholesale;internet sales(Except for products that require a license for sale);Information Consulting Service(Not including licensing information consulting services);Educational Consulting Services(Education and training activities that do not include licensing approval);Standardized service;Conference and Exhibition Services;business training(Does not include education and training,Vocational skills training and other licensed training);marketing planning;Medical equipment rental;Purchasing agency service;Enterprise member point management service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.